A novel frameshift mutation of the \textit{NF1} gene in a Chinese pedigree with neurofibromatosis type 1

Sir,

Neurofibromatosis are a group of hereditary disorders, characterized by an autosomal dominant pattern of inheritance. The most common variant is neurofibromatosis type 1 (90%), which affects one in every 3500 individuals. Neurofibroma is the cutaneous hallmark of neurofibromatosis type 1. This tumor is often accompanied by café-au-lait macules, axillary freckling, Lisch nodules of the iris and bone lesions and these patients are predisposed to develop malignancies. Neurofibromatosis type 1 is caused by mutation of the \textit{NF1} gene which is located on chromosome 17q11.2 and contains sixty exons; it also spans more than 300 kb of genomic deoxyribonucleic acid. Neurofibromin, which is encoded by \textit{NF1} gene is a large protein (with 2818 amino acids) expressed in all cells and is particularly expressed at a high level in neurons, Schwann cells, glial cells and leukocytes. \textit{NF1} gene mutation leads to haploinsufficiency of neurofibromin thereby resulting in increased risk of benign or malignant neoplasms.

Two patients in one pedigree were clinically diagnosed with neurofibromatosis type 1 at Xuanwu Hospital, Capital Medical University, China. The proband was a 17-year-old boy born with four large café-au-lait macules on his waist and buttocks. He gradually developed other café-au-lait macules on his trunk which increased in size from 1 cm \times 2 cm to 23 cm \times 14 cm. At the age of 10, a tender mass was found on the dorsum of his left foot. This

\includegraphics{figure1.png}

\textbf{Figure 1:} Neurofibroma seen on the dorsum of the left foot in the proband

\includegraphics{figure2.png}

\textbf{Figure 2:} Multiple café-au-lait macules and neurofibromas on the mother’s back

\textit{© 2017 Indian Journal of Dermatology, Venereology, and Leprology | Published by Wolters Kluwer – Medknow}

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

\textbf{How to cite this article:} Chen J, Liang Y. Novel glycine substitution G2037R of \textit{COL7A1} in a Chinese boy with pretibial epidermolysis bullosa treated with oral olopatadine hydrochloride and topical Vitamin E. Indian J Dermatol Venereol Leprol 2017;83:229-31.

Received: October, 2016

Accepted: June, 2016.

1. Hamada T, Fukuda S, Ishii N, Abe T, Nagata K, Koro O, et al. A Japanese family with dominant pretibial dystrophic epidermolysis bullosa: Identification of a new glycine substitution in the triple-helical collagenous domain of type VII collagen. J Dermatol Sci 2009;54:212-4.

2. Liu YH, Shang X, Li ZT, Wu YM, Li LF, Xu XM. A novel \textit{COL7A1} gene mutation causing pretibial epidermolysis bullosa: Report of a Chinese family with intra-familial phenotypical diversity. Gene 2013;524:377-80.
Letters to the Editor

Figure 3: Frameshift mutation c. 3236_3240dupTTCTA of partial deoxyribonucleic acid sequence of the NF1 gene. The mother and the son had the same mutation.

mass was resected twice, but recurred. The recurrent mass had a diameter of 4 cm [Figure 1]. Histopathological features of the lesion were consistent with neurofibroma.

The second patient was the boy’s mother who was 53 years old. She was born with a large café-au-lait macule on her back. With age, she developed multiple subcutaneous neurofibromas and an increased number of café-au-lait macules all over her body [Figure 2]. She had had mild dyspnoea and chest pain 40 years back, which on evaluation, was attributed to a mediastinal mass compressing the left lung. Histopathology of the resected tumour revealed a neurofibroma. No abnormality was found on ophthalmologic examination or magnetic resonance imaging (MRI) of the central nervous system.

This study was approved by the Ethical Committee of Xuanwu Hospital, Capital Medical University. We collected 5 ml of peripheral blood from each patient for genomic deoxyribonucleic acid extraction. All exons and exon/intron boundaries of the NF1 gene were amplified by polymerase chain reaction. Deoxyribonucleic acid samples from 100 controls with a normal phenotype were screened for novel NF1 mutations to exclude the possibility of polymorphism. After comparing the sequence with the reference complementary deoxyribonucleic acid (accession number NM_000267.3 in GenBank), we identified the mutations. A novel heterozygous frameshift mutation (c. 3236_3240dupTTCTA) in exon 25 of the NF1 gene mutation was identified in both the boy and his mother [Figure 3]. This germline mutation produced a premature stop codon and resulted in a truncated protein instead of the full-length neurofibromin. No mutants were identified among the 100 normal control subjects. Hence, this novel germline mutation was probably the disease-causing mutation.

Neurofibromatosis type 1 is a complex hereditary neurocutaneous syndrome caused by mutations in the NF1 gene, one of the largest genes in the human genome. The NF1 gene has significantly high mutation rates caused by the large number of coding exons and mutational heterogeneity. To date, more than 1000 mutations of several types have been reported including chromosomal abnormalities, insertions, point mutations, deletions, stop mutations, 3’-untranslated region mutations and splicing mutations. The novel frameshift mutation we detected significantly affected the function of the NF1 gene and resulted in an early termination of protein synthesis. In eukaryotes, nonsense-mediated decay is a surveillance mechanism observed for premature termination of translation. In this pathway, premature termination promotes the recruitment of a set of factors that degrade messenger ribonucleic acids undergoing this process. As a result, the truncated proteins would not be synthesised. Both these factors may have played a role in the occurrence of the disease. The limitation of our study is that the truncated neurofibromin was not verified on a protein level; hence it is not fully proved whether the disease is caused by the frameshift mutation. The clinical presentation of neurofibromatosis type 1 is highly heterogeneous, ranging from the cutaneous manifestations alone to a number of medical complications. In this study, two patients had the same genotype but their phenotypes were different. It has been suggested that feature-specific modifier genes unlinked to the neurofibromatosis type 1 locus, epigenetic alterations or environmental factors may contribute to such variable expression.

In conclusion, the c. 3236_3240dupTTCTA mutation in NF1 gene appears to be the cause of neurofibromatosis type 1 in this pedigree. This study adds a novel mutation to the spectrum of NF1 mutations and provides probable evidence that the loss or diminished function of the neurofibromin leads to neurofibromatosis type 1.

Acknowledgments
The authors sincerely thank the proband and his family members for participation in this study and also all the other participants for their consent to this study.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

Xuefei Lin, Hui Chen, Wei Zhu, Shi Lian
Department of Dermatology, Xuanwu Hospital, Capital Medical University, Xuanwu District, Beijing 100053, China

Correspondence: Prof. Wei Zhu,
Department of Dermatology, Xuanwu Hospital, Capital Medical University, 45 Changchun St., Xuanwu District, Beijing 100053, China.
E-mail: zhuwei@xwh.cmu.edu.cn

Prof. Shi Lian,
Department of Dermatology and Venereology, Capital Medical University, 10 Youannmen St, Fengtai District, Beijing 100069, China.
E-mail: drlianshi@sina.com

References
1. Ars E, Kruyer H, Morell M, Pros E, Serra E, Ravella A, et al. Recurrent mutations in the NF1 gene are common among neurofibromatosis
type 1 patients. J Med Genet 2003;40:e82.
2. Alkindy A, Chuzhanova N, Kini U, Cooper DN, Upadhyaya M. Genotype-phenotype associations in neurofibromatosis type 1 (NF1): An increased risk of tumor complications in patients with NF1 splice-site mutations? Hum Genomics 2012;6:12.
3. Bottillo I, Ahlquist T, Brekke H, Danielsen SA, van den Berg E, Mertens F, et al. Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. J Pathol 2009;217:693-701.
4. Kervestin S, Jacobson A. NMD: A multifaceted response to premature translational termination. Nat Rev Mol Cell Biol 2012;13:700-12.
5. Sabbagh A, Pasmant E, Laurendeau I, Parfait B, Barbarot S, Guillot B, et al. Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. Hum Mol Genet 2009;18:2768-78.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Lin X, Chen H, Zhu W, Lian S. A novel frameshift mutation of the NF1 gene in a Chinese pedigree with neurofibromatosis type 1. Indian J Dermatol Venereol Leprol 2017;83:231-3.
Received: October, 2015. Accepted: May, 2016.
© 2017 Indian Journal of Dermatology, Venereology, and Leprology | Published by Wolters Kluwer - Medknow